ProtaGene

Activities: Manufacturing Research & Development Analysis

Trending Articles

  1. EnergiVault trial delivers peak performance Full-scale testing of the EnergiVault cold thermal energy storage system from Organic Heat Exchangers (O-Hx) has seen performance exceed expectations in areas including peak...
  2. TrakCel and Lonza complete gene therapy manufacturing and orchestration solutions integration milestone TrakCel, supplier of cellular orchestration solutions for clinical trials and commercial therapies to the cell and gene therapy (CGT) industry, has completed a milestone in its...
  3. Marchesini Group focuses on pharma blister and cartridges packaging The Integra 320 and the FB 220 will be showcased at the FCE Pharma and Expo Pack in South America
  4. Sanofi-Synthelabo to acquire Arixtra interests from Organon Sanofi-Synthelabo, of Paris, France, has reached agreement with Organon to acquire all the latter's interests relating to Arixtra (fondaparinux sodium), idraparinux and other...
  5. Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected...

Upcoming event

CPhI North America

2–4 June 2026 | Exhibition | Pennsylvania, US See all

Related Content

Manufacturing

ProtaGene and Merck partner to deliver end-to-end biologics testing

The duo will combine ProtaGene's early-stage biologics expertise with Merck's BioReliance GMP testing infrastructure, offering biopharmaceutical customers an integrated testing solution across the full drug development lifecycle
Finance

New capital strengthens ProtaGene's advanced analytical leadership in the biologics and CGT markets

ProtaGene GmbH, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, announces additional investment from Ampersand Capital Partners
Regulatory

Confronting molecular bioanalysis challenges in gene therapy development

As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growing. It’s exciting to be part of today’s gene therapy development community; however, three issues are at the top of the industry’s mind—the regulatory landscape, critical molecular bioanalysis considerations (biodistribution, transgene expression, and vector shedding), and assay-related challenges
Manufacturing

Navigating CMC challenges in NBE and therapeutic antibody development

Insights by Dr Thomas Flad, Senior Director of Solutions & Innovation at ProtaGene, as he poses solutions to the difficulty matching analytical resources with analytical demands
Manufacturing

Join ProtaGene and ADRES for a joint webinar on regulatory and analytical aspects of comparability in biologics development

From research through product commercialisation, ProtaGene provides advanced, integrated, and complete protein and gene analytic capabilities
Drug Delivery

ProtaGene appoints new scientific and commercial leadership

The move is set to support evolving needs of biologic and cell and gene therapy innovators
Drug Delivery

ProtaGene appoints new Chief Executive Officer

Kaiser will drive the continued innovation and growth strategy for the company's advanced analytical services
Subscribe now